MEDIPOST Co. Ltd (078160) - Total Liabilities

Latest as of September 2025: ₩109.40 Billion KRW ≈ $74.14 Million USD

Based on the latest financial reports, MEDIPOST Co. Ltd (078160) has total liabilities worth ₩109.40 Billion KRW (≈ $74.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of MEDIPOST Co. Ltd to track the company's year-over-year net asset growth rate.

MEDIPOST Co. Ltd - Total Liabilities Trend (2011–2024)

This chart illustrates how MEDIPOST Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See MEDIPOST Co. Ltd (078160) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

MEDIPOST Co. Ltd Competitors by Total Liabilities

The table below lists competitors of MEDIPOST Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Terns Pharmaceuticals Inc
NASDAQ:TERN
USA $17.59 Million
Solborn Inc
KQ:035610
Korea ₩51.71 Billion
Talga Group Ltd
F:TGX
Germany €5.87 Million
AXON PARTNERS GRP EO -10
F:XE1
Germany €8.31 Million
Shotspotter Inc
NASDAQ:SSTI
USA $63.58 Million
CX Technology Corp
TW:2415
Taiwan NT$6.81 Billion
Hansol Holdings Co Ltd
KO:004150
Korea ₩243.81 Billion
Fuzetec Technology Co Ltd
TWO:6642
Taiwan NT$395.65 Million

Liability Composition Analysis (2011–2024)

This chart breaks down MEDIPOST Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MEDIPOST Co. Ltd market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.96 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.29 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how MEDIPOST Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for MEDIPOST Co. Ltd (2011–2024)

The table below shows the annual total liabilities of MEDIPOST Co. Ltd from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩161.69 Billion
≈ $109.57 Million
+19.12%
2023-12-31 ₩135.74 Billion
≈ $91.99 Million
-37.68%
2022-12-31 ₩217.82 Billion
≈ $147.61 Million
+130.22%
2021-12-31 ₩94.61 Billion
≈ $64.12 Million
-8.38%
2020-12-31 ₩103.27 Billion
≈ $69.98 Million
+1.11%
2019-12-31 ₩102.13 Billion
≈ $69.21 Million
+108.69%
2018-12-31 ₩48.94 Billion
≈ $33.17 Million
+21.75%
2017-12-31 ₩40.20 Billion
≈ $27.24 Million
+11.81%
2016-12-31 ₩35.95 Billion
≈ $24.36 Million
-1.36%
2015-12-31 ₩36.45 Billion
≈ $24.70 Million
-46.89%
2014-12-31 ₩68.63 Billion
≈ $46.51 Million
+142.10%
2013-12-31 ₩28.35 Billion
≈ $19.21 Million
+40.26%
2012-12-31 ₩20.21 Billion
≈ $13.70 Million
+20.64%
2011-12-31 ₩16.75 Billion
≈ $11.35 Million
--

About MEDIPOST Co. Ltd

KQ:078160 Korea Biotechnology & Medical Research
Market Cap
$86.93 Million
₩128.27 Billion KRW
Market Cap Rank
#19614 Global
#960 in Korea
Share Price
₩8340.00
Change (1 day)
+9.88%
52-Week Range
₩7520.00 - ₩28000.00
All Time High
₩72522.12
About

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more